Victoria Richon (Ribon Therapeutics)

Ri­bon Ther­a­peu­tics is look­ing to break the mold for PARP in­hibitors and has a slate of Big Phar­ma back­ers on board

Ri­bon Ther­a­peu­tics broke three years of ra­dio si­lence back in ear­ly 2019 to spread the word of its $65 mil­lion Se­ries B round. Now, two …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.